13F filer · CIK 1559565
Sofinnova Management VIII, L.L.C.
Menlo Park, CA · filing since Q4 2016 · last filing Feb 14, 2018
Reported value
$178.4M
$-11.2M vs prior
Positions
9
New / sold out
0 / 1
Added / reduced
0 / 1
Turnover
0.0%
buys $0 · sells $942.5K
Top-10 weight
100.0%
Biggest buys vs Q1 2017
No new or increased positions this quarter.
Biggest sells vs Q1 2017
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Sold out | Sophiris Bio Inc. | -200,000 | -100.0% | $-566.0K |
| Reduced | Spark Therapeutics, Inc. | -6,302 | -0.9% | $-376.5K |
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2017
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | Aclaris Therapeutics, Inc.COMMON STOCK | 1,539,480 | $41.8M | 23.40% |
| 2 | Spark Therapeutics, Inc.COMMON STOCK | 693,128 | $41.4M | 23.20% |
| 3 | ObsEva SACOMMON STOCK | 3,749,623 | $32.1M | 17.97% |
| 4 | Versartis, Inc.COMMON STOCK | 1,563,260 | $27.3M | 15.29% |
| 5 | Natera, Inc.COMMON STOCK | 1,550,280 | $16.8M | 9.43% |
| 6 | Auris Medical Holding AGCOMMON SHARES | 7,818,175 | $5.6M | 3.15% |
| 7 | Mirna Therapeutics, Inc.COMMON STOCK | 2,974,812 | $5.0M | 2.78% |
| 8 | Innocoll Holdings PLCORDINARY SHARES | 2,103,173 | $4.8M | 2.69% |
| 9 | Histogenics CorporationCOMMON STOCK | 2,077,040 | $3.7M | 2.08% |